Existing investor syndicate supports atrial shunting as effective therapy for heart failure patients TEWKSBURY, Mass., June 9, 2022 /PRNewswire/ — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure (HF), today announced the closing of a $54 million equity financing …
Trending at Lumira Ventures
Corvia Medical Completes Randomization In REDUCE LAP-HF II Pivotal Trial And Gains FDA Authorization To Provide Continued Access For The Corvia Atrial Shunt
TEWKSBURY, Mass., Nov. 17, 2020 /PRNewswire/ — Corvia Medical, Inc., a company dedicated to transforming the treatment of heart failure (HF), today announced completion of randomization in its REDUCE LAP-HF II global, pivotal trial. The trial is evaluating the Corvia® Atrial Shunt (IASD®) …
Corvia Medical’s Global Clinical Trial Begins Randomization in Japanese Patients
TEWKSBURY, Mass. /PRNewswire/ — Corvia Medical, Inc., a privately-held company with a first-in-class structural heart device to treat heart failure, today announced the first Japanese patients were randomized in Toyama and Hyogo under a clinical trial authorization from the Pharmaceutical …
Corvia Medical’s Interatrial Shunt Device (IASD®) Receives Breakthrough Device Designation for Heart Failure
TEWKSBURY, MA – Corvia Medical, Inc., a privately-held company with a first-in-class structural heart device to treat heart failure, today announced the U.S. Food and Drug Administration (FDA) has granted the company a Breakthrough Device designation for its InterAtrial Shunt …
Corvia Medical & PhysIQ Partner in Phase 3 Heart Failure Clinical Trial
Corvia Medical is actively enrolling and sponsoring a first-of-its-kind 100+ site, global, Phase 3 clinical trial leveraging continuous multivariate wearable sensor data and artificial intelligence (AI) based analytics to evaluate the clinical efficacy of it’s InterAtrial Shunt Device (IASD®) in …
Edwards Lifesciences announces exclusive right to acquire Corvia Medical, Inc.
IRVINE, Calif., — Edwards Lifesciences Corporation EW, -0.99% the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced two strategic transactions involving companies with structural heart disease technologies. Edwards has invested $35 million in …
Corvia Medical Announces Strong Positive One-Year Data From REDUCE LAP-HF I Randomized, Sham-Controlled Clinical Trial
Corvia Medical, Inc., a privately-held company with a first-in-class structural heart device to treat heart failure, today announced one-year follow-up data from the REDUCE LAP-HF I clinical study of its Interatrial Shunt Device (IASD®). The IASD is the world’s first …
Corvia Medical Announces Enrollment Of First Patients In Pivotal Trial Of The IASD® System II For The Treatment Of Heart Failure
ANAHEIM, CA – November 14, 2017 — Corvia Medical, Inc., a privately-held medical device company that developed a first-in-class transcatheter structural heart device to treat heart failure, today announced that it has enrolled the first patients in its global multicenter …
Corvia Medical Announces CE Mark Approval And Enrollment Of First Patients In Randomized Clinical Study
TEWKSBURY, Mass., May 12, 2016 /PRNewswire/ — Corvia Medical, Inc., a privately-held medical device company that has developed a first-in-class structural heart device to treat heart failure, today announced CE Mark approval of its InterAtrial Shunt Device (IASD®). The IASD …
Corvia Medical Receives IDE Approval For REDUCE LAP-HF I Clinical Study & Announces Agreement With Strategic Partner For Exclusive Option To Purchase Company
TEWKSBURY, Mass., March 7, 2016 /PRNewswire/ — Corvia Medical, Inc., a privately-held medical device company that developed a first-in-class transcatheter structural heart device to treat heart failure, today announced that it has received Investigational Device Exemption (IDE) approval from the …
DC Devices Completes Enrollment in Clinical Trial of the First Transcatheter Device to Treat Diastolic Heart Failure; Announces Name Change to Corvia Medical
TEWKSBURY, MA – June 22, 2015 — DC Devices, Inc., a medical device company pioneering first-in-class structural heart devices for heart failure, today announced that it has completed enrollment and implants in the REDUCE LAP-HF trial, an open label, multi-center, …
DC Devices Closes $34m Series D Financing To Complete Clinical Evaluation Of The First Transcatheter Device To Treat Diastolic Heart Failure
TEWKSBURY, MA – July 1, 2014 — DC Devices, Inc., a medical device company pioneering first-in-class structural heart devices, has closed a $34 million Series D financing round. Accelmed led the round with contributions from existing investors Third Rock Ventures, …
DC Devices Raises $9M from Canadian & U.S. VC Funds
DC Devices Inc. has raised US$9 Million from a consortium of investors. Lumira Capital joined the financing along with existing investors Third Rock Ventures and General Catalyst. Gerry Brunk, managing director of Lumira, joined the company’s board of directors. Tewksbury, …